Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies

Hong Kong and Lake Zurich, Illinois (ots/PRNewswire) -

Fenwal, Inc. of Lake Zurich, Illinois, and Golden Meditech (stock
code: 801.HK) of Hong Kong, announced today they have agreed to form
a joint venture in China to focus on blood collection and transfusion
products for the fast-growing Chinese medical market.

The transaction is expected to be completed in early 2010,
subject to the signing of a definitive agreement and other customary
company and regulatory conditions.

Medical professionals in China are expected to benefit from the
combination of Fenwal's technological leadership in blood collection,
separation, preservation and transfusion, and Golden Meditech's
expertise in China's blood-related medical device and blood-banking
fields. Fenwal will own 51 percent of the joint venture and Golden
Meditech will own 49 percent.

The joint venture will operate from Beijing and serve customers
throughout China. Initially, the joint venture will focus on sales
and distribution of a range of Fenwal and Golden Meditech products,
including Fenwal's AMICUS(R) system, a cell-separation system used to
collect platelets; Golden Meditech's 3000H Plasma Exchange system,
which is designed to remove toxins from patients' blood; and related
supplies used to collect, process, preserve and transfuse blood and
blood components.

"Fenwal is a pioneer and leader in advanced blood technologies,"
said Mr. Kam Yuen, Golden Meditech's chairman and chief executive
officer. "We're looking to bring together the leadership, knowledge
and capabilities of both companies to expand and customize our
offerings for blood collection and transfusion medicine in China."

"Golden Meditech is a respected medical leader with extensive
knowledge of the China market," said Ron K. Labrum, Fenwal's
president and chief executive officer. "Its people, technologies and
infrastructure will complement Fenwal's current offerings in China.
Together, we expect to create new opportunities to expand the market
for advanced blood technologies that will benefit patients throughout
China."

About Fenwal

Fenwal, Inc. became an independent company in 2007, but its roots
go back to 1949 with the founding of Fenwal Laboratories. Fenwal
developed the first flexible, disposable container for blood
collection, eliminating complications associated with glass
containers and allowing blood to be separated into therapeutic
components. Today, the company's products and advanced collection and
separation technologies are used throughout the world to help ensure
a safe and available supply of lifesaving blood and blood products.
Fenwal Inc. is based in Lake Zurich, Illinois. For more information,
please visit http://www.fenwalinc.com .

About Golden Meditech

Founded in 2000, Golden Meditech was listed on the Growth
Enterprise Market of the Stock Exchange of Hong Kong Limited (HKEX)
in December 2001, as the first high-tech medical device enterprise
that went public outside of the PRC, and was granted the main board
listing in June 2009. During the past few years, thanks to its great
efforts in innovation and market expansion, as well as its
first-mover abilities in emerging markets, Golden Meditech's medical
devices, cord blood banking services and natural herbal medicines
have established leading positions. Going forward, Golden Meditech
will continue its pursuit of becoming China's leading integrated
medical group through organic growth, acquisitions and strategic
investments. For more information, please visit
http://www.goldenmeditech.com .

For Golden Meditech
Dennis Haikuan Lu
+852-3605-8138
dennis@goldenmeditech.com
For Fenwal, Inc.
Tanya Tyska
+1-847-550-2732
Tanya.Tyska@fenwalinc.com
Geoffrey Fenton
+1-847-550-2321
Geoffrey.Fenton@fenwalinc.com

ots Originaltext: Golden Meditech; Fenwal, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For Golden Meditech - Dennis Haikuan Lu, +852-3605-8138, or
dennis@goldenmeditech.com; or For Fenwal, Inc. - Tanya Tyska,
+1-847-550-2732, or Tanya.Tyska@fenwalinc.com, or Geoffrey Fenton,
+1-847-550-2321, or Geoffrey.Fenton@fenwalinc.com